Article
Virology
Eugenio Milano, Aurelia Ricciardi, Raffaella Casciaro, Elisabetta Pallara, Elda De Vita, Davide F. Bavaro, Angela Maria Vittoria Larocca, Pasquale Stefanizzi, Silvio Tafuri, Annalisa Saracino
Summary: This study evaluated the immunogenicity and safety of the BNT162b2 vaccine in people living with HIV infection. The results showed that the vaccine regimen was immunogenic and well-tolerated in this population, with the majority of patients developing positive titer antibodies. No severe adverse events were reported.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Immunology
Theerada Assawasaksakul, Tanat Lertussavavivat, Seelwan Sathitratanacheewin, Nont Oudomying, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Yong Poovorawan, Yingyos Avihingsanon, Nawaporn Assawasaksakul, Supranee Buranapraditkun, Wonngarm Kittanamongkolchai
Summary: This study compared the immunogenicity and safety of three COVID-19 vaccine regimens in patients with SLE and RA. The study found that adenovirus-vectored and adenovirus-vectored/mRNA vaccines elicited a stronger immune response and may be more suitable for patients receiving immunosuppressive therapy.
Article
Biochemistry & Molecular Biology
Angela Choi, Matthew Koch, Kai Wu, Laurence Chu, LingZhi Ma, Anna Hill, Naveen Nunna, Wenmei Huang, Judy Oestreicher, Tonya Colpitts, Hamilton Bennett, Holly Legault, Yamuna Paila, Biliana Nestorova, Baoyu Ding, David Montefiori, Rolando Pajon, Jacqueline M. Miller, Brett Leav, Andrea Carfi, Roderick McPhee, Darin K. Edwards
Summary: The study demonstrates that both the mRNA-1273 COVID-19 vaccine and its variant-modified booster doses are safe and effective in improving neutralizing antibody titers against various virus variants.
Article
Biochemistry & Molecular Biology
Ni Tien, Yu-Chang Chang, Po-Ku Chen, Hui-Ju Lin, Shih-Hsin Chang, Joung-Liang Lan, Po-Ren Hsueh, Ching-Kun Chang, Der-Yuan Chen
Summary: This study evaluated the immunogenicity and safety of three types of vaccines in patients with immune-mediated inflammatory diseases (IMID) and healthcare workers (HCWs). The study found that mRNA-1273 or BNT162b2 vaccines had higher immunogenicity compared to the AZD1222 vaccine. Immunogenicity was enhanced after the second dose of any vaccine type in all IMID patients. Patients receiving abatacept/rituximab therapy had lower immunogenicity compared to those receiving other DMARDs. All three SARS-CoV-2 vaccines showed acceptable safety profiles, with injection site reactions being the common adverse events.
Article
Immunology
Sebastian Mondaca, Benjamin Walbaum, Nicole Le Corre, Marcela Ferres, Alejandro Valdes, Constanza Martinez-Valdebenito, Cinthya Ruiz-Tagle, Patricia Macanas-Pirard, Patricio Ross, Betzabe Cisternas, Patricia Perez, Olivia Cabrera, Valentina Cerda, Ivana Ormazabal, Aldo Barrera, Maria E. Prado, Maria I. Venegas, Silvia Palma, Richard Broekhuizen, Alexis M. Kalergis, Susan M. Bueno, Manuel A. Espinoza, M. Elvira Balcells, Bruno Nervi
Summary: Cancer patients receiving chemotherapy treatment have a lower immune response to SARS-CoV-2 vaccines. Our study demonstrated that booster vaccines elicit strong humoral and cellular responses among cancer patients receiving chemotherapy, regardless of the type of vaccine used as a priming dose. The homologous vaccine regimen was associated with higher neutralizing antibody positivity and total antibody levels.
Review
Biochemistry & Molecular Biology
Hui Xuan Lim, Masita Arip, Abdul Aziz Al-Fattah Yahaya, Seyed Davoud Jazayeri, Sibrandes Poppema, Chit Laa Poh
Summary: The SARS-CoV-2 infections, first detected in Wuhan in December 2019, led to a global pandemic in 2020 with more than 180 million cases and 3.9 million deaths. The rapid development of vaccine candidates has shown promising results, with some achieving over 90% efficacy in preventing COVID-19.
FRONTIERS IN BIOSCIENCE-LANDMARK
(2021)
Article
Hematology
J. Erika Haydu, Jenny S. Maron, Robert A. Redd, Kathleen M. E. Gallagher, Stephanie Fischinger, Jeffrey A. Barnes, Ephraim P. Hochberg, P. Connor Johnson, R. W. Takvorian, Katelin Katsis, Daneal Portman, Jade Ruiters, Sidney Sechio, Mary Devlin, Connor Regan, Kimberly G. Blumenthal, Aleena Banerji, Allen D. Judd, Krista J. Scorsune, Brianne M. McGree, Maryanne M. Sherburne, Julia M. Lynch, James I. Weitzman, Matthew Lei, Camille N. Kotton, Anand S. Dighe, Marcela V. Maus, Galit Alter, Jeremy S. Abramson, Jacob D. Soumerai
Summary: This prospective study demonstrates that SARS-CoV-2 vaccination induces functional T-cell and antibody responses in patients with CLL. The serologic response to the vaccine is more common in treatment-naive patients. Most patients had functional spike-specific T-cell responses in interferon-gamma release assays.
Article
Immunology
Ilaria Mormile, Francesca Della Casa, Angelica Petraroli, Alessandro Furno, Francescopaolo Granata, Giuseppe Portella, Francesca Wanda Rossi, Amato de Paulis
Summary: This study evaluated the efficacy and safety of mRNA COVID-19 vaccines in patients with systemic lupus erythematosus (SLE). The results showed that the vaccines produced a satisfactory antibody response in SLE patients without influencing disease activity.
Article
Biochemistry & Molecular Biology
Francesca La Gualana, Francesca Maiorca, Ramona Marrapodi, Francesca Villani, Marzia Miglionico, Stefano Angelo Santini, Fabio Pulcinelli, Laura Gragnani, Silvia Piconese, Massimo Fiorilli, Stefania Basili, Milvia Casato, Lucia Stefanini, Marcella Visentini
Summary: New-generation mRNA and adenovirus vectored vaccines show immunogenic, inflammatory, and immunomodulatory properties against SARS-CoV-2 spike protein. A noninflammatory tolerogenic mRNA vaccine (MOGm1 psi) has been developed to induce expansion of antigen-specific regulatory T (Treg) cells. The BNT162b2 mRNA vaccine and MOGm1 psi have similar effects on Treg cells, but differ in lipid carrier composition. More studies are needed to confirm the capacity of BNT162b2 and MOGm1 psi in promoting Treg cell expansion.
Review
Oncology
Zehong Huang, Yingying Su, Tianying Zhang, Ningshao Xia
Summary: This study reviewed the safety and effectiveness of 12 most progressed COVID-19 vaccines and found that most vaccines have shown positive results in clinical trials or real-world studies. However, challenges remain in maximizing vaccine effectiveness, including rapid vaccine coverage, strategies for variant strains, and long-term safety monitoring.
FRONTIERS OF MEDICINE
(2022)
Article
Immunology
Anussara Prayongrat, Patjaya Noppaving, Thitiporn Chobarporn, Natthinee Sudhinaraset, Nattaya Teeyapun, Nussara Pakvisal, Watsamon Jantarabenjakul, Jiratchaya Sophonphan, Chawalit Lertbutsayanukul, Yong Poovorawan
Summary: Diminished immune response was observed in cancer patients receiving radiotherapy after COVID-19 vaccination. This study evaluated the immune response and safety profile in 53 cancer patients undergoing radiotherapy who received the COVID-19 vaccine. The results showed that the immunogenicity was fair after the first dose, but achieved a higher seroconversion rate after the second dose. However, the immunologic response in these patients was still lower than in healthy individuals, suggesting the need for additional preventive strategies.
Review
Immunology
Subbiah Jeeva, Ki-Hye Kim, Chong Hyun Shin, Bao-Zhong Wang, Sang-Moo Kang
Summary: The review discusses the emergence of mRNA vaccines for other infectious diseases following the success of COVID-19 vaccines, detailing the structural elements needed for designing mRNA vaccine constructs and providing updates on mRNA vaccines for SARS-CoV-2, influenza virus, and other pathogens. Unique features of mRNA vaccine platforms and future perspectives are also explored.
Article
Respiratory System
Chao Cao, Feng Qiu, Chengcheng Lou, Lingling Fang, Fang Liu, Jingjing Zhong, Weijie Sun, Weiping Ding, Xiaopin Yu, Qinhong Xu, Ran Wang, Liemin Ruan, Qifa Song
Summary: This retrospective cohort study examined the local and systemic reactions in patients with allergic disease who received inactivated SARS-CoV-2 vaccines. The study found that patients with allergic disease reported higher rates of pain at the injection site and systemic reactions compared to the control group. However, the administration of the vaccine was safe and well tolerated by all participants.
RESPIRATORY RESEARCH
(2022)
Article
Immunology
Vidya Arankalle, Archana Kulkarni-Munje, Ruta Kulkarni, Sonali Palkar, Rahul Patil, Jitendra Oswal, Sanjay Lalwani, Akhilesh Chandra Mishra
Summary: This study assessed the immune response of healthcare workers to COVISHIELD and COVAXIN vaccines. The results showed that COVISHIELD generated higher neutralizing antibody titers while COVAXIN exhibited a stronger T-cell response. However, after 6 months, there was a decrease in neutralizing antibody titers, emphasizing the need for early booster immunization.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, Research & Experimental
Jonathan L. Golob, Njira Lugogo, Adam S. Lauring, Anna S. Lok
Summary: Multiple vaccines targeting the SARS-CoV-2 surface glycoprotein have shown high efficacy in preventing symptomatic COVID-19, with success attributed to open science collaboration, harmonized clinical trials, and the altruism of study participants. Challenges remain in manufacturing and distributing vaccines, with a focus now shifting towards ensuring equitable global vaccination against COVID-19.
Article
Dermatology
Ulrich Seidl, Andreas Pinter, Dagmar Wilsmann-Theis, Sietske Poortinga, Kirsten Morrison, Ulrich Mrowietz, Sascha Gerdes
Summary: Guselkumab, an approved medication for moderate-to-severe psoriasis and psoriatic arthritis, showed high efficacy in a real-world setting, with absolute PASI proving to be a valuable tool for measuring treatment outcomes.
DERMATOLOGIC THERAPY
(2022)
Article
Gastroenterology & Hepatology
Huy Duc Le, Theresa Pflaum, Johannes Labrenz, Soner Sari, Fabienne Bretschneider, Florian Tran, Arne Lassen, Susanna Nikolaus, Silke Szymczak, Diana Kormilez, Philip Rosenstiel, Stefan Schreiber, Konrad Aden, Christoph Roecken
Summary: This study evaluated histological disease activity in UC patients and found that the Nancy index is a reliable measure. However, there was poor agreement in the assessment of NI grade 1. It is important to specify histological characteristics leading to NI grade 1.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Genetics & Heredity
Neha Mishra, Konrad Aden, Johanna Blase, Nathan Baran, Dora Bordoni, Florian Tran, Claudio Conrad, Diana Avalos, Charlot Jaeckel, Michael Scherer, Signe B. Sorensen, Silja H. Overgaard, Berenice Schulte, Susanna Nikolaus, Guillaume Rey, Gilles Gasparoni, Paul A. Lyons, Joachim L. Schultze, Joern Walter, Vibeke Andersen, Emmanouil T. Dermitzakis, Stefan Schreiber, Philip Rosenstiel
Summary: This study investigated the dynamics of gene expression and DNA methylation in blood samples of IBD patients treated with TNF antagonist infliximab. The results showed that early shifts in gene expression and DNA methylation could predict the response to anti-TNF treatment. This finding can help identify IBD patients who are unlikely to benefit from TNF antagonists.
Article
Gastroenterology & Hepatology
Jan Kral, Radislav Nakov, Vera Lanska, Brigida Barberio, Nicolas Benech, Andreas Blesl, Eduard Brunet, Tiago Capela, Lauranne Derikx, Gabriele Dragoni, Aileen Eek, Catarina Frias-Gomes, Georgiana-Emmanuela Gilca-Blanariu, Leah Gilroy, Philip Harvey, Anna Kagramanova, Haluk Tarik Kani, Tom Konikoff, Matthias Lessing, Gorm Madsen, Vaidota Maksimaityte, Maria Miasnikova, Ivana Mikolasevic, Vladimir Milivojevic, Daniele Noviello, Dmytro Oliinyk, Arpad Patai, Anthea Pisani, Adonis Protopapas, Iago Rodriguez-Lago, Philipp Schreiner, Vita Skuja, Florian Tran, Marie Truyens, Marcin Wlodarczyk, Hubert Zatorski, Bram Verstockt, Jonathan Philip Segal
Summary: Variability in IBD practice exists across Europe, with marked differences observed between high and low GDP countries. High GDP countries have higher availability of IBD-specific training, IBD units, multidisciplinary meetings, IBD nurses, nurse-led IBD clinics, IBD dieticians, psychologists, and telemedicine. Treat-to-target approaches are implemented everywhere, but access to biologicals and small molecules differs significantly.
DIGESTIVE DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Kerstin Wolk, Dagmar Wilsmann-Theis, Katrin Witte, Theresa-Charlotte Brembach, Christian Kromer, Sascha Gerdes, Kamran Ghoreschi, Kristian Reich, Rotraut Moessner, Robert Sabat
Summary: This study found elevated levels of interleukin-19 (IL-19) in the blood of palmoplantar pustulosis (PPP) patients. The results also showed that treatment with apremilast (a PDE4 inhibitor) significantly reduced IL-19 levels and improved the condition of PPP patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Xiaolin Liu, Nina van Beek, Aleksa Cepic, Nadia A. Andreani, Cecilia J. Chung, Britt M. Hermes, Kaan Yilmaz, Sandrine Benoit, Kossara Drenovska, Sascha Gerdes, Regine Glaeser, Matthias Goebeler, Claudia Guenther, Anabelle von Georg, Christoph M. Hammers, Maike M. Holtsche, Franziska Huebner, Dimitra Kiritsi, Franziska Schauer, Beke Linnenmann, Laura Huilaja, Kaisa Tasanen-Maatta, Snejina Vassileva, Detlef Zillikens, Christian D. Sadik, Enno Schmidt, Saleh Ibrahim, John F. Baines
Summary: Bullous pemphigoid patients have altered gut microbiota composition and function, with decreased microbial diversity and overall changed microbial community. Disease-associated gut microbial features, including reduced Faecalibacterium prausnitzii and increased pathways related to gamma-aminobutyric acid metabolism, are observed in BP patients. These findings suggest that gut microbiota alterations may play a role in the development of bullous pemphigoid.
FRONTIERS IN IMMUNOLOGY
(2023)
Meeting Abstract
Dermatology
Lena Moebus, Elke Rodriguez, Inken Harder, Nicole Boraczynski, Silke Szymczak, Matthias Huebenthal, Dora Stoelzl, Sascha Gerdes, Andreas Kleinheinz, Susanne Abraham, Annice Heratizadeh, Christiane Handrick, Eva Haufe, Thomas Werfel, Jochen Schmitt, Stephan Weidinger
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Meeting Abstract
Dermatology
Dariusch Mortazawi, Rolf Ostendorf, Andreas Schwinn, Freya-Sophie Lenz, Simmy Jacobsen, Judita Makuc, Juliane Behrens, Sarah Tabori, Sascha Gerdes
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Meeting Abstract
Dermatology
Selina Patt, Matthias Augustin, Sascha Gerdes, Nina Magnolo, Rotraut Moessner, Robert Nemeth, Cornelia Paul, Andreas Pinter, Petra Staubach-Renz, Ansgar Weyergraf, Dagmar Wilsmann-Theis
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Meeting Abstract
Dermatology
Ulrich Seidl, Ann-Sophie Bohne, Kaeding Merit, Laura Bauer, Ulrike Wehkamp, Michael Weichental, Sascha Gerdes, Thomas Schwarz, Guido Heine
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Meeting Abstract
Dermatology
Rachel Sommer, Lukas Westphal, Ulrich Mrowietz, Sascha Gerdes, Matthias Augustin
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Meeting Abstract
Dermatology
Sascha Gerdes, Sebastian Zimmer, Jens-Joachim Bruecher, Anke Suess, Friedemann Taut, Simmy Jacobsen, Judita Makuc, Juliane Behrens, Sarah Tabori, Matthias Augustin
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Meeting Abstract
Dermatology
Felix Lauffer, Andreas Pinter, Georgios Kokolakis, Sascha Gerdes, Bengt Hoepken, Nicola Tilt, Susanne Wiegratz, Florian Hinze, M. Sebastian
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Florian Tran, Susanna Nikolaus, Florian Schrinner, Julia Kumpers, Anna Sophie Lessing, Matthias Lessing, Laura K. Sievers, Philip Rosenstiel, Andre Franke, Konrad Aden, Stefan Schreiber
Meeting Abstract
Dermatology
E. Rodriguez, L. Moebus, I. Harder, N. Boraczynski, S. Szymczak, M. Huebenthal, D. Stoelzl, S. Gerdes, A. Kleinheinz, S. Abraham, A. Heratizadeh, K. Schaekel, C. Handrick, E. Haufe, T. Werfel, J. Schmitt, S. Weidinger
EXPERIMENTAL DERMATOLOGY
(2022)